Original InvestigationMyocarditis in Patients Treated With Immune Checkpoint Inhibitors
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Mahmood has been supported by the Sarnoff Cardiovascular Research Foundation. Drs. Chen and Gupta are supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support grant P30 CA008748. Dr. Thavendiranathan is supported by Canadian Institutes of Health Research New Investigator Award (FRN 147814). Dr. Neilan was supported in part through the Kohlberg Foundation, American Heart Association Fellow to Faculty Award 12FTF12060588, NIH/National Heart, Lung, and Blood Institute grants 1R01HL130539-01A1, 1R01HL137562-01A1, and K24HL113128-06, and NIH/Harvard Center for AIDS Research grant P30 AI060354. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr. Mahmood has received consultancy fees from OMR Globus, Alpha Detail, and Opinion Research Team. Dr. Nohria has received research support from Amgen; and has been a consultant for Takeda Oncology. Dr. Heinzerling has received consultancy, advisory board, and speaker fees from MSD, BMS, Roche, Novartis, Amgen, and Curevac. Dr. Sullivan has been a consultant to Merck and Novartis. Dr. Moslehi has served as a consultant/advisor for Novartis, Pfizer, Bristol-Myers Squibb, Takeda/Millennium, Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi-Sankyo, and Regeneron. Dr. Groarke has received research support from Amgen.
Dr. Neilan has received advisory fees from Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.